Table 1.
Characteristics of the patients in the primary cohort and validation cohort.
| Number of patients(%) | ||
|---|---|---|
| Characteristic | Primary cohort (n = 289) | Validation cohort (n = 156) |
| Gender | ||
| Male | 249 (86.1) | 129 (82.7) |
| Female | 40 (13.9) | 27 (17.3) |
| Age (years) | ||
| Median | 52 | 49 |
| Range | 15-73 | 24–77 |
| Karnofsky performance score (KPS) | ||
| >70 | 240 (83.0) | 127 (81.4) |
| ≤70 | 49 (17.0) | 29 (18.6) |
| T category | ||
| T1-2 | 100 (34.6) | 20 (12.8) |
| T3-4 | 189 (65.4) | 136 (87.2) |
| N category | ||
| N0-1 | 81 (28.0) | 22 (14.1) |
| N2-3 | 208 (72.0) | 134 (85.9) |
| Sites of metastasis | ||
| Bone | 195 (67.4) | 100 (76.3) |
| Liver | 96 (33.2) | 40 (25.6) |
| Lung | 56 (17.6) | 34 (21.8) |
| Others | 20 (6.9) | 18 (11.5) |
| Multi-organ metastases (≥ 2) | ||
| Yes | 71 (24.6) | 50 (32.1) |
| No | 218 (75.4) | 106 (67.9) |
| Numbers of metastatic lesions | ||
| 1 | 56 (19.3) | 31 (19.9) |
| 2-5 | 105 (36.3) | 42 (26. 9) |
| ≥ 6 | 128 (44.4) | 83 (53.2) |
| Hemoglobin, Hb (g/L) | ||
| <120 | 39 (13.4) | 17 (10.9) |
| ≥120 | 250 (86.6) | 139 (89.1) |
| Alkaline phosphatase, ALP (IU/L) | ||
| ≤110 | 224 (77.6) | 126 (81.8) |
| >110 | 65 (22.4) | 30(19.2) |
| Lactate dehydrogenase, LDH (IU/L) | ||
| ≤245 | 187 (64.7) | 95 (60.9) |
| >245 | 102 (35.3) | 61 (39.1) |
| Chemotherapy cycles | ||
| 1-3 | 86 (29.8) | 39 (25.0) |
| ≥4 | 203 (70.2) | 117 (75.0) |
| Chemotherapy response | ||
| CR+PR | 162 (56.1) | 88 (56.4) |
| SD | 93 (32.2) | 36 (23.1) |
| PD | 34 (11.8) | 32 (20.5) |